Physician profile
Tara E Seery
NPI 1043415961
$84,057.67
in general payments reported to CMS, 2019-2025
67 companies · $11K in 2025
The $11K reported for 2025 was more than what 89% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,365 · 2020: $19K · 2021: $17K · 2022: $5,873 · 2023: $15K · 2024: $8,593 · 2025: $11K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $16K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $12K · Food and Beverage: $3,620 · Travel and Lodging: $2,084.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $16,462.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $12,112.00 |
| Food and Beverage | $3,619.80 |
| Travel and Lodging | $2,084.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $25,979.73 | 2019-2025 | Onivyde, Somatuline Depot |
| Eli Lilly and Company | $15,525.00 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $8,681.28 | 2019-2023 | |
| Astellas Pharma US INC | $7,776.82 | 2020-2025 | Vyloy, Xospata |
| Astellas Pharma Global Development | $4,344.00 | 2024-2025 | Vyloy |
| E.R. Squibb & Sons, L.L.C. | $3,795.22 | 2019-2025 | Opdivo, Opdualag |
| Springworks Therapeutics, INC. | $2,700.00 | 2024 | Ogsiveo |
| Helsinn Therapeutics (U.S.), INC. | $2,520.00 | 2021 | |
| Taiho Oncology, INC. | $1,796.68 | 2019-2023 | |
| Exelixis INC. | $1,281.25 | 2022-2023 | Cabometyx |
| Lilly USA, LLC | $813.97 | 2019-2023 | Retevmo, Jaypirca |
| Merck Sharp & Dohme LLC | $790.91 | 2019-2023 | Keytruda, Lynparza |
| Amgen INC. | $751.12 | 2019-2023 | Lumakras, Vectibix, Xgeva |
| Eisai INC. | $683.51 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $541.67 | 2020-2023 | Enhertu, Tagrisso, Imfinzi |
Show all 65 companies
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tara Seery listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.